Tumor organoid and tumor-on-a-chip equipped next generation precision medicine
Source abstract
Abstract
Abstract Recently, significant advancements have been witnessed in various in vitro treatment evaluation models, especially organoids and organs-on-chips. In vitro culture of cancer cells and drug screening are key technical components in functional oncology precision medicine. However, most studies primarily focus on constructing models using established cell lines, with limited integration with clinical diagnosis or patient treatment. This review provides a brief overview of precision medicine models, followed by discussions on the broad spectrum of applications involving two-dimensional tumor cell culture, patient-derived tumor xenograft models, tumor organoids, and tumors-on-chips. It highlights the success rate of patient-derived tumor organoids construction and their application in clinical trials. Recent advancements in tumors-on-chips and organoids-on-chips are elaborated on, alongside with integration of other new generation technologies. Additionally, this review summarizes the advantages and constraints associated with tumor organoids and tumors-on-chips, underscoring their crucial role in the advancement of personalized medicine.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Innovative Microfluidic and Catalytic Techniques Innovation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. What is precision medicine?10.1183/13993003.00391-2017 ↗
2. Implementation of whole-genome and transcriptome sequencing into clinical cancer care10.1200/PO.22.00245 ↗
3. Personalized medicine: motivation, challenges, and progress10.1016/j.fertnstert.2018.05.006 ↗
4. Precision medicine and therapies of the future10.1111/epi.16539 ↗
5. Why rare disease needs precision medicine-and precision medicine needs rare disease10.1016/j.xcrm.2022.100530 ↗
6. The road to precision medicine: eliminating the “One Size Fits All” approach in Alzheimer’s disease10.1016/j.biopha.2022.113337 ↗
7. Precision medicine, AI, and the future of personalized health care10.1111/cts.12884 ↗
8. Global Oncology Trends 2025: Adopting new therapies as modalities shift and expenditures rise
9. The future of precision cancer therapy might be to try everything10.1038/d41586-024-00392-2 ↗
10. Mathematical models of tumor cell proliferation: a review of the literature10.1080/14737140.2018.1527689 ↗
11. Automated evaluation of tumor spheroid behavior in 3D culture using deep learning-based recognition10.1016/j.biomaterials.2021.120770 ↗
12. A storm in a teacup–A biomimetic lung microphysiological system in conjunction with a deep-learning algorithm to monitor lung pathological and inflammatory reactions10.1016/j.bios.2022.114772 ↗
13. Sentinel supervised lung-on-a-chip: a new environmental toxicology platform for nanoplastic-induced lung injury10.1016/j.jhazmat.2023.131962 ↗
14. Epidermis-on-a-chip system to develop skin barrier and melanin mimicking model10.1177/20417314231168529 ↗
15. A new approach of using organ-on-a-chip and fluid–structure interaction modeling to investigate biomechanical characteristics in tissue-engineered blood vessels10.3389/fphys.2023.1210826 ↗
16. Organoids-on-a-chip for personalized precision medicine10.1002/adhm.202401843 ↗
17. Promises and challenges of organoid-guided precision medicine10.1016/j.medj.2021.08.005 ↗
18. Tumor organoids: opportunities and challenges to guide precision medicine10.1016/j.ccell.2021.07.020 ↗
19. FDA announces plan to phase out animal testing requirement for monoclonal antibodies and other drugs
20. Human organs-on-chips for disease modelling, drug development and personalized medicine10.1038/s41576-022-00466-9 ↗
21. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors10.1089/adt.2014.573 ↗
22. Patient-derived xenograft models: an emerging platform for translational cancer research10.1158/2159-8290.CD-14-0001 ↗
23. Comparative studies of cellular viability levels on 2D and 3D in vitro culture matrices10.1007/s10616-017-0139-7 ↗
24. A practical guide to hydrogels for cell culture10.1038/nmeth.3839 ↗
25. Cellulose nanofibers and composites: an insight into basics and biomedical applications10.1016/j.jddst.2022.103601 ↗
26. Advances in high throughput cell culture technologies for therapeutic screening and biological discovery applications10.1002/btm2.10627 ↗
27. Efficient large-scale 2D culture system for human induced pluripotent stem cells and differentiated cardiomyocytes10.1016/j.stemcr.2017.08.025 ↗
28. Emerging roles of 3D-culture systems in tackling tumor drug resistance10.20517/cdr.2023.93 ↗
29. Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review10.5599/admet.1513 ↗
30. Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer10.3892/or.2015.3767 ↗
31. Is it time to start transitioning from 2D to 3D cell culture?10.3389/fmolb.2020.00033 ↗
32. The challenge of ovarian tissue culture: 2D versus 3D culture10.1186/s13048-021-00892-z ↗
33. Microfluidic devices for cell cultivation and proliferation10.1063/1.4826935 ↗
34. Similarities and differences in metabolites of tongue cancer cells among two‐and three‐dimensional cultures and xenografts10.1111/cas.14749 ↗
35. Concepts of extracellular matrix remodelling in tumour progression and metastasis10.1038/s41467-020-18794-x ↗
36. Modeling physiological events in 2D vs. 3D cell culture10.1152/physiol.00036.2016 ↗
37. A novel three-dimensional immune oncology model for high-throughput testing of tumoricidal activity10.3389/fimmu.2018.00857 ↗
38. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response10.1186/s40880-018-0270-7 ↗
39. The genomic landscape of response to EGFR blockade in colorectal cancer10.1038/nature14969 ↗
40. Interrogating open issues in cancer precision medicine with patient-derived xenografts10.1016/S0167-8140(18)30534-6 ↗
41. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes10.1038/nm.2454 ↗
42. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response10.1038/nm.3954 ↗
43. Personalized in vitro and in vivo cancer models to guide precision medicine10.1158/2159-8290.CD-16-1154 ↗
44. Application of highly immunocompromised mice for the establishment of Patient-Derived Xenograft (PDX) models10.3390/cells8080889 ↗
45. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology10.1038/s43018-022-00337-6 ↗
46. Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research10.1002/ame2.12349 ↗
47. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs10.1158/0008-5472.CAN-14-0761 ↗
48. Interrogating open issues in cancer precision medicine with patient-derived xenografts10.1038/nrc.2016.140 ↗
49. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment10.1038/aps.2015.92 ↗
50. Heterogeneity and molecular landscape of melanoma: implications for targeted therapy10.1186/s43556-024-00182-2 ↗
51. Organoid technology in cancer precision medicine10.1016/j.canlet.2019.04.039 ↗
52. A brief history of organoids10.1152/ajpcell.00120.2020 ↗
53. A new method by which sponges may be artificially reared10.1126/science.25.649.912 ↗
54. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells10.1073/pnas.78.12.7634 ↗
55. Embryonic stem cell lines, derived from human blastocysts10.1126/science.282.5391.1145 ↗
56. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche10.1038/nature07935 ↗
57. Self-formation of optic cups and storable stratified neural retina from human ESCs10.1016/j.stem.2012.05.009 ↗
58. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells10.1016/j.stem.2013.11.010 ↗
59. Unlimited in vitro expansion of adult bi‐potent pancreas progenitors through the Lgr5/R‐spondin axis10.1038/emboj.2013.204 ↗
60. Single luminal epithelial progenitors can generate prostate organoids in culture10.1038/ncb3047 ↗
61. Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function10.1016/j.stem.2014.07.012 ↗
62. Recent advances in lung organoid development and applications in disease modeling10.1172/JCI170500 ↗
63. Quantification of regenerative potential in primary human mammary epithelial cells10.1242/dev.123554 ↗
64. Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-derived dorsomedial telencephalic tissue10.1038/ncomms9896 ↗
65. Characterization of primary models of human trophoblast10.1242/dev.199749 ↗
66. Human organoids in basic research and clinical applications10.1038/s41392-022-01024-9 ↗
67. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers10.1126/science.aao2774 ↗
68. Patient-derived tumour organoids: a bridge between cancer biology and personalised therapy10.1016/j.actbio.2022.04.050 ↗
69. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity10.1038/s41467-022-29857-6 ↗
70. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer10.1158/1078-0432.CCR-20-4116 ↗
71. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer10.1158/2159-8290.CD-18-0349 ↗
72. A rectal cancer organoid platform to study individual responses to chemoradiation10.1038/s41591-019-0584-2 ↗
73. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer10.1016/j.stem.2019.10.010 ↗
74. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids10.1016/j.cell.2018.07.009 ↗
75. An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile10.1186/s13046-022-02263-y ↗
76. A patient-derived organoid-based radiosensitivity model for the prediction of radiation responses in patients with rectal cancer10.3390/cancers13153760 ↗
77. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution10.1007/s13402-022-00728-y ↗
78. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids10.1038/s41596-020-00474-1 ↗
79. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages10.1038/s41467-020-15548-7 ↗
80. Patient‐derived organoids can guide personalized‐therapies for patients with advanced breast cancer10.1002/advs.202101176 ↗
81. A living biobank of breast cancer organoids captures disease heterogeneity10.1016/j.cell.2017.11.010 ↗
82. Personalized chordoma organoids for drug discovery studies10.1126/sciadv.abl3674 ↗
83. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer10.1007/s13402-022-00707-3 ↗
84. Patient‐derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy10.1002/advs.202204097 ↗
85. Organoid cultures as preclinical models of non–small cell lung cancer10.1158/1078-0432.CCR-19-1376 ↗
86. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study10.1016/j.xcrm.2022.100911 ↗
87. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening10.1038/s41467-019-11867-6 ↗
88. Cultivation of clear cell renal cell carcinoma patient-derived organoids in an air-liquid interface system as a tool for studying individualized therapy10.3389/fonc.2020.01775 ↗
89. Mouse and human urothelial cancer organoids: a tool for bladder cancer research10.1073/pnas.1803595116 ↗
90. Tumor evolution and drug response in patient-derived organoid models of bladder cancer10.1016/j.cell.2018.03.017 ↗
91. An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity10.1038/s41591-019-0422-6 ↗
92. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids10.1016/j.devcel.2023.04.012 ↗
93. Developing organoids from ovarian cancer as experimental and preclinical models10.1016/j.stemcr.2020.03.004 ↗
94. A patient-derived glioblastoma organoid model and biobank recapitulates inter-and intra-tumoral heterogeneity10.1016/j.cell.2019.11.036 ↗
95. Three-dimensional culture of human breast epithelial cells: the how and the why
96. Challenges in validation of combination treatment strategies for CRC using patient-derived organoids10.1186/s13046-024-03173-x ↗
97. Long‐term expanding human airway organoids for disease modeling10.15252/embj.2018100300 ↗
98. Applied models and molecular characteristics of small cell lung cancer10.3389/pore.2024.1611743 ↗
99. Prostate organoids: emerging experimental tools for translational research10.1172/JCI169616 ↗
100. AT cell‐engaging tumor organoid platform for pancreatic cancer immunotherapy10.1002/advs.202300548 ↗